Literature DB >> 16082378

Ionizing radiation: a genetic switch for cancer therapy.

J J Mezhir1, K D Smith, M C Posner, N Senzer, B Yamini, D W Kufe, R R Weichselbaum.   

Abstract

Gene therapy of cancer represents a promising but challenging area of therapeutic research. The discovery of radiation-inducible genes led to the concept and development of radiation-targeted gene therapy. In this approach, promoters of radiation-inducible genes are used to drive transcription of transgenes in the response to radiation. Constructs in which the radiation-inducible promoter elements activate a transgene encoding a cytotoxic protein are delivered to tumors by adenoviral vectors. The tumoricidal effects are then localized temporally and spatially by X-rays. We review the conceptual development of TNFerade, an adenoviral vector containing radiation-inducible elements of the early growth response-1 promoter upstream of a cDNA encoding human tumor necrosis factor-alpha. We also summarize the preclinical work and clinical trials utilizing this vector as a treatment for diverse solid tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16082378     DOI: 10.1038/sj.cgt.7700879

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  10 in total

1.  Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

Authors:  Weibo Cai; Zachary J Kerner; Hao Hong; Jiangtao Sun
Journal:  Biochem Insights       Date:  2008-07-22

Review 2.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

3.  A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

Authors:  T Y Seiwert; T Darga; D Haraf; E A Blair; K Stenson; E E W Cohen; J K Salama; V Villaflor; M E Witt; M W Lingen; R R Weichselbaum; E E Vokes
Journal:  Ann Oncol       Date:  2012-10-26       Impact factor: 32.976

Review 4.  Is EGR1 a potential target for prostate cancer therapy?

Authors:  Delphine Gitenay; Véronique T Baron
Journal:  Future Oncol       Date:  2009-09       Impact factor: 3.404

5.  Early growth response protein-1 promoter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-Flurorouracil on nasopharyngeal carcinoma.

Authors:  Guimiao Lin; Marie Chia-Mi Lin; Suxia Lin; Hong Yao; Shuihong Yu; Wanxian Yi; Gaixia Xu; Samuel Sai-Ming Ng; Siping Chen; Jing Yu; Xiaomei Wang; Baoxue Yang
Journal:  Cancer Biother Radiopharm       Date:  2012-09       Impact factor: 3.099

6.  Retargeted adenoviruses for radiation-guided gene delivery.

Authors:  S A Kaliberov; L N Kaliberova; H Yan; V Kapoor; D E Hallahan
Journal:  Cancer Gene Ther       Date:  2016-08-05       Impact factor: 5.987

7.  Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs.

Authors:  George E Naoum; Zeng B Zhu; Donald J Buchsbaum; David T Curiel; Waleed O Arafat
Journal:  Clin Transl Med       Date:  2017-03-01

8.  Transcriptional control of Flt3 ligand targeted by fluorouracil-induced Egr-1 promoter in hematopoietic damage.

Authors:  Nan Du; Xuetao Pei; Jinming Zhou; Hui Zhao; Xiaosong Li; Yan Fu; Yixin Hao
Journal:  J Biomed Sci       Date:  2009-09-21       Impact factor: 8.410

9.  Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice.

Authors:  S Ganai; R B Arenas; N S Forbes
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

10.  Reversion of p-glycoprotein-mediated multidrug resistance in human leukemic cell line by diallyl trisulfide.

Authors:  Qing Xia; Zhi-Yong Wang; Hui-Qing Li; Yu-Tao Diao; Xiao-Li Li; Jia Cui; Xue-Liang Chen; Hao Li
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-12       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.